Silverfin false false 31/12/2024 01/01/2024 31/12/2024 Bethany Lampl 15/06/2023 William Narey 31/12/2013 02 September 2025 The principal activity of the company is that of investing in UK trading companies and provision of support to said investments. 08828816 2024-12-31 08828816 bus:Director1 2024-12-31 08828816 bus:Director2 2024-12-31 08828816 2023-12-31 08828816 core:CurrentFinancialInstruments 2024-12-31 08828816 core:CurrentFinancialInstruments 2023-12-31 08828816 core:ShareCapital 2024-12-31 08828816 core:ShareCapital 2023-12-31 08828816 core:RetainedEarningsAccumulatedLosses 2024-12-31 08828816 core:RetainedEarningsAccumulatedLosses 2023-12-31 08828816 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-12-31 08828816 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-12-31 08828816 core:LandBuildings 2023-12-31 08828816 core:PlantMachinery 2023-12-31 08828816 core:Vehicles 2023-12-31 08828816 core:OfficeEquipment 2023-12-31 08828816 core:LandBuildings 2024-12-31 08828816 core:PlantMachinery 2024-12-31 08828816 core:Vehicles 2024-12-31 08828816 core:OfficeEquipment 2024-12-31 08828816 core:CostValuation 2023-12-31 08828816 core:AdditionsToInvestments 2024-12-31 08828816 core:CostValuation 2024-12-31 08828816 bus:OrdinaryShareClass1 2024-12-31 08828816 2024-01-01 2024-12-31 08828816 bus:FilletedAccounts 2024-01-01 2024-12-31 08828816 bus:SmallEntities 2024-01-01 2024-12-31 08828816 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 08828816 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 08828816 bus:Director1 2024-01-01 2024-12-31 08828816 bus:Director2 2024-01-01 2024-12-31 08828816 core:DevelopmentCostsCapitalisedDevelopmentExpenditure core:TopRangeValue 2024-01-01 2024-12-31 08828816 core:LandBuildings core:TopRangeValue 2024-01-01 2024-12-31 08828816 core:PlantMachinery 2024-01-01 2024-12-31 08828816 core:Vehicles 2024-01-01 2024-12-31 08828816 core:OfficeEquipment 2024-01-01 2024-12-31 08828816 2023-01-01 2023-12-31 08828816 core:LandBuildings 2024-01-01 2024-12-31 08828816 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 08828816 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 08828816 (England and Wales)

# GLOBAL INHALATION EQUIPMENT LIMITED

### Unaudited Financial Statements
For the financial year ended 31 December 2024
Pages for filing with the registrar

GLOBAL INHALATION EQUIPMENT LIMITED

## Unaudited Financial Statements

For the financial year ended 31 December 2024

Contents

GLOBAL INHALATION EQUIPMENT LIMITED

## BALANCE SHEET

As at 31 December 2024
GLOBAL INHALATION EQUIPMENT LIMITED

## BALANCE SHEET (continued)

As at 31 December 2024

| Note | 2024 |  | 2023
|  | £ |  | £
Fixed assets |  |  |  |
Tangible assets | 4 | 266,008 |  | 285,173
Investments | 5 | 542,599 |  | 67
|  | 808,607 |  | 285,240
Current assets |  |  |  |
Debtors | 6 | 170,590 |  | 726,400
Cash at bank and in hand |  | 2,568 |  | 12,725
|  | 173,158 |  | 739,125
Creditors: amounts falling due within one year | 7 | ( 1,509,290) |  | ( 1,487,279)
Net current liabilities |  | (1,336,132) |  | (748,154)
Total assets less current liabilities |  | (527,525) |  | (462,914)
Provision for liabilities |  | ( 23,393) |  | 0
Net liabilities |  | ( 550,918) |  | ( 462,914)
Capital and reserves |  |  |  |
Called-up share capital | 8 | 9,000 |  | 9,000
Profit and loss account |  | ( 559,918 ) |  | ( 471,914 )
Total shareholder's deficit |  | ( 550,918) |  | ( 462,914)

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The member has not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Global Inhalation Equipment Limited (registered number: 08828816) were approved and authorised for issue by the Board of Directors on 02 September 2025. They were signed on its behalf by:

Bethany Lampl Director |

GLOBAL INHALATION EQUIPMENT LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
GLOBAL INHALATION EQUIPMENT LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Global Inhalation Equipment Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Lowin House, Tregolls Road, Truro, TR1 2NA, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Balance Sheet date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Balance Sheet date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.
Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on tax rates and laws substantively enacted at the balance sheet date. Deferred tax assets and liabilities are not discounted.

##### Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Development costs | 4 years straight line

##### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a [straight-line, reducing balance] basis over its expected useful life, as follows:

Land and buildings | 50 years straight line
Plant and machinery | 20 % reducing balance
Vehicles | 20 % reducing balance
Office equipment | 20 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

##### Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account as described below.

##### Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value through profit or loss if the shares are publicly traded or their fair value can otherwise be measured reliably. Other investments are measured at cost less impairment.

##### Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.
Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

##### Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.
The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Balance Sheet date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).
When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

#### 2. Employees

| 2024 |  | 2023
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including directors | 0 |  | 0

#### 3. Intangible assets

| Development costs |  | Total
| £ |  | £
Cost |  |  |
At 01 January 2024 | 42,754 |  | 42,754
At 31 December 2024 | 42,754 |  | 42,754
Accumulated amortisation |  |  |
At 01 January 2024 | 42,754 |  | 42,754
At 31 December 2024 | 42,754 |  | 42,754
Net book value |  |  |
At 31 December 2024 | 0 |  | 0
At 31 December 2023 | 0 |  | 0

#### 4. Tangible assets

| Land and buildings |  | Plant and machinery |  | Vehicles |  | Office equipment |  | Total
| £ |  | £ |  | £ |  | £ |  | £
Cost |  |  |  |  |  |  |  |  |
At 01 January 2024 | 277,260 |  | 1,995 |  | 30,332 |  | 6,053 |  | 315,640
Disposals | 0 |  | 0 |  | ( 30,332) |  | 0 |  | ( 30,332)
At 31 December 2024 | 277,260 |  | 1,995 |  | 0 |  | 6,053 |  | 285,308
Accumulated depreciation |  |  |  |  |  |  |  |  |
At 01 January 2024 | 8,714 |  | 1,341 |  | 17,464 |  | 2,948 |  | 30,467
Charge for the financial year | 5,545 |  | 131 |  | 0 |  | 621 |  | 6,297
Disposals | 0 |  | 0 |  | ( 17,464) |  | 0 |  | ( 17,464)
At 31 December 2024 | 14,259 |  | 1,472 |  | 0 |  | 3,569 |  | 19,300
Net book value |  |  |  |  |  |  |  |  |
At 31 December 2024 | 263,001 |  | 523 |  | 0 |  | 2,484 |  | 266,008
At 31 December 2023 | 268,546 |  | 654 |  | 12,868 |  | 3,105 |  | 285,173

#### 5. Fixed asset investments

Investments in subsidiaries

| 2024
| £
Cost |
At 01 January 2024 | 66
Additions | 542,532
At 31 December 2024 | 542,598
Carrying value at 31 December 2024 | 542,598
Carrying value at 31 December 2023 | 66

Details of undertakings
The company holds 66% of the ordinary share capital of Certus Biomedical Limited, a company incorporated in England and Wales. The registered office of the named subsidiary entity is Unit 7c A30 Business Park, Indian Queens, Newquay, England, TR9 6FZ and the principal activity is to service and supply medical equipment.
On 17 October 2024 the company converted £542,532 of its debt due from Certus Biomedical Limited into one new Ordinary A share.

| Investments in associates |  | Total
| £ |  | £
Cost or valuation before impairment |  |  |
At 01 January 2024 | 1 |  | 1
At 31 December 2024 | 1 |  | 1
Carrying value at 31 December 2024 | 1 |  | 1
Carrying value at 31 December 2023 | 1 |  | 1

Detail of undertaking:
The company holds 50% of the ordinary shares in Hypneuma Limited a company incorporated in England and Wales. The registered office is The Health And Wellbeing Innovation Centre, Treliske, Truro, Cornwall, United Kingdom, TR1 3FF, and the principal activity is the manufacture of medical and dental instruments and supplies.
Shortly after the year end the company acquired the remaining 50% ordinary shareholding in Hypneuma and became the sole shareholder.

#### 6. Debtors

| 2024 |  | 2023
| £ |  | £
Trade debtors | 2,160 |  | 0
Amounts owed by Group undertakings | 76,171 |  | 618,009
Other debtors | 92,259 |  | 108,391
| 170,590 |  | 726,400

#### 7. Creditors: amounts falling due within one year

| 2024 |  | 2023
| £ |  | £
Other taxation and social security | 14,616 |  | 17,210
Other creditors | 1,494,674 |  | 1,470,069
| 1,509,290 |  | 1,487,279

#### 8. Called-up share capital

| 2024 |  | 2023
| £ |  | £
Allotted, called-up and fully-paid |  |  |
9,000 Ordinary shares of £ 1.00 each | 9,000 |  | 9,000

#### 9. Related party transactions

Other related party transactions

| 2024 |  | 2023
| £ |  | £
Certus Biomedical Ltd - GIE owns 66% of ordinary shares and 1 ordinary A share in Certus Biomedical. | 78,331 |  | 618,009
Hypneuma Ltd - The Shareholder with control of GIE owns 50% of shares in Hypneuma. | 64,000 |  | 69,317
Somni Scientific LLC - Company in which a director has an interest. | (447,315) |  | (447,315)
General Anaesthetic Services Ltd - Company in which a director has an interest. | (266,391) |  | (247,975)
Pleasure Wave Ltd - Director of GIE owns 100% of shares in Pleasure Wave. | (4,541) |  | (3,726)
Gigrealm International Ltd - The directors of GIE have an interest in Gigrelm. | 32,800 |  | 32,800